TELIP

Telip is a biotechnology company focused on overcoming the endosomal barrier, a major hurdle in the delivery of large-molecule therapeutics to intracellular targets. The company's proprietary Targeted Endosomal Escape and Lysosomal Inhibition Platform (TELIP) utilizes pH-responsive polymers that trigger the release of therapeutic payloads from endosomes into the cell's cytosol. This modular technology is designed to enhance the delivery of diverse modalities, including proteins, antibodies, and nucleic acids, which are otherwise degraded or trapped within the cell. Telip is leveraging this platform to develop a pipeline of therapies for oncology, immunology, and rare genetic disorders where reaching the intracellular space is essential for therapeutic success. The company was founded as a spin-out from the University of Washington, building on decades of research in polymer science and drug delivery.